

are needed, strategies should not preclude application of standard bundle practices.

#### ACKNOWLEDGMENTS

*Financial support:* This research was supported in part by a CDC Cooperative Agreement (FOA#CK11-001) with the Epicenters for the Prevention of Healthcare Associated Infections. A.M.V. received grant support from a National Institute of Health T32 institutional training grant.

*Potential conflicts of interest:* All authors report no conflicts of interest relevant to this article.

**Ana M. Vaughan, MD, MPH;<sup>1</sup>**  
**Rachael Ross, MPH;<sup>1</sup>**  
**Margaret M. Gilman, CIC;<sup>2</sup>**  
**Lauren Satchell, BA;<sup>2</sup>**  
**Susan Ditaranto, RN, MHA, NEA-BC;<sup>3</sup>**  
**Anne F. Reilly, MD, MPH;<sup>4</sup>**  
**Leslie S. Kersun, MD, MSCE;<sup>5</sup>**  
**Amanda Shanahan, RN, BSN;<sup>5</sup>**  
**Susan E. Coffin, MD, MPH, FSHEA, FPIDS;<sup>1</sup>**  
**Julia Shaklee Sammons, MD, MSCE<sup>6</sup>**

Affiliations: 1. Department of Pediatrics, Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; 2. Department of Infection Prevention and Control, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; 3. Department of Medical/Medical Subspecialty Nursing, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; 4. Department of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; 5. Department of Inpatient Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; 6. Perelman School of Medicine, Department of Pediatrics, Department of Infection Prevention and Control, Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

Address correspondence to Julia Shaklee Sammons, MD, MSCE, Department of Infection Prevention and Control, The Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, A level – Room #AE20, Philadelphia, PA 19104 (sammonsj@email.chop.edu).

PREVIOUS PRESENTATION. Part of these data were presented as a poster at IDWeek 2016 in New Orleans, Louisiana, on October 27, 2016, abstract #58502.

*Infect Control Hosp Epidemiol* 2017;38:1385–1387

© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2017/3811-0025. DOI: 10.1017/ice.2017.188

#### REFERENCES

1. Highlighted NHSN January 2013 Patient Safety Component (PSC) Manual updates. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/PDFs/Newsletters/January-2013-PSC-Updates.pdf>. Published 2013. Accessed November 26, 2016.
2. 2016 National Healthcare Safety Network (NHSN) Patient Safety Component Manual. Centers for Disease Control and Prevention. [https://www.cdc.gov/nhsn/pdfs/pscmanual/pscmanual\\_current.pdf](https://www.cdc.gov/nhsn/pdfs/pscmanual/pscmanual_current.pdf). Published 2016. Accessed November 26, 2016.
3. Epstein L, See I, Edwards JR, Magill SS, Thompson ND. Mucosal barrier injury laboratory-confirmed bloodstream infections (MBI-LCBI): descriptive analysis of data reported to National Healthcare Safety Network (NHSN), 2013. *Infect Control Hosp Epidemiol* 2015;37:2–7.
4. See I, Iwamoto M, Allen-Bridson K, Horan T, Magill SS, Thompson ND. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new national healthcare safety network definition. *Infect Control Hosp Epidemiol* 2013;34:769–776.
5. Metzger KE, Rucker Y, Callaghan M, et al. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients. *Infect Control Hosp Epidemiol* 2015;36:119–124.

## Black Box Oxidizers

*To the Editor*—Burgess et al<sup>1</sup> describe important findings on how to effectively kill glutaraldehyde-resistant mycobacterial strains. Based on the data described, oxidizing agents seem to be effective against them in short exposure times at elevated temperatures, similar to the results reported by other authors.<sup>2–4</sup> While the preparation of the aldehydes is described in detail (ie, final concentration of the active ingredient), this important piece of information is completely missing for all 3 Steris products based on peracetic acid or hydrogen peroxide. Minimum effective concentration (MEC) values are described for the aldehyde-based products, but no minimal regrowth concentration (MRC) values are provided for the oxidizers. Mentioning only the name of a product is not sufficient for the scientific community; readers may also want to understand how exactly the solutions were prepared (especially when at least 1 product seems to be a powder or when products consist of more than 1 component). Readers may also want to see the final concentration of each active ingredient for all 3 products (eg, peracetic acid and hydrogen peroxide). Only these details will allow us to critically evaluate the effectiveness of the biocidal agents described in the study.

#### ACKNOWLEDGMENTS

*Financial support:* No financial support was provided relevant to this article.

*Potential conflicts of interest:* The author has worked for Bode Chemie GmbH, Hamburg, Germany.

**Günter Kampf, MD**

Affiliations: University Medicine Greifswald, Greifswald, Germany.

Address correspondence to Günter Kampf, MD, University Medicine Greifswald, Institute for Hygiene and Environmental Medicine, Walter-Rathenau-Straße 49 A, 17475 Greifswald, Germany (guenter.kampf@uni-greifswald.de).

*Infect Control Hosp Epidemiol* 2017;38:1387–1388

© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2017/3811-0026. DOI: 10.1017/ice.2017.199

## REFERENCES

1. Burgess W, Margolis A, Gibbs S, Duarte RS, Jackson M. Disinfectant susceptibility profiling of glutaraldehyde-resistant nontuberculous Mycobacteria. *Infect Control Hosp Epidemiol* 2017;38:784–791.
2. Lynam PA, Babb JR, Fraise AP. Comparison of the mycobactericidal activity of 2% alkaline glutaraldehyde and 'Nu-Cidex' (0.35% peracetic acid). *J Hosp Infect* 1995;30:237–240.
3. Stanley PM. Efficacy of peroxygen compounds against glutaraldehyde-resistant mycobacteria. *Am J Infect Control* 1999; 27:339–343.
4. Griffiths PA, Babb JR, Fraise AP. Mycobactericidal activity of selected disinfectants using a quantitative suspension test. *J Hosp Infect* 1999;41:111–121.